Clinical context An adult with B-cell precursor acute lymphoblastic leukemia develops fever, hypotension, hypoxemia, confusion, word-finding difficulty, and tremor 18 hours after a continuous blinatumomab infusion begins, raising concern for concurrent cytokine release syndrome and neurologic toxicity. Review the trend and select the best interpretation and next plan.
Trend
Choose your responses, then check the answer.
Explanation
Resolution of fever, hypotension, and hypoxemia suggests the systemic inflammatory component is improving, but persistent language dysfunction and worsening tremor show unresolved neurologic toxicity. Blinatumomab must remain interrupted while urgent neurologic management continues.
Quick answer Do not mistake improving CRS for resolution of persistent neurologic toxicity.
Why this is correct Systemic and neurologic effects can recover on different timelines. Treatment cannot be restarted solely because blood pressure and temperature improve.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: BLINCYTO (blinatumomab)Cytokine release syndrome, neurologic toxicity including ICANS, interruption, corticosteroid treatment, and monitoring
Clinical contextAn adult with B-cell precursor acute lymphoblastic leukemia develops fever, hypotension, hypoxemia, confusion, word-finding difficulty, and tremor 18 hours after a continuous blinatumomab infusion begins, raising concern for concurrent cytokine release syndrome and neurologic toxicity.